Kintor Pharmaceutical Limited (SEHK: 9939)
Health Care · Biotechnology · CN
HK$1.81
-2.17% today · -24.8% 1Y
Kintor Pharmaceutical Limited (SEHK: 9939) operates in the Biotechnology industry within the Health Care sector. The company is valued at $113.69M and employs 123 people.
Over the last twelve months the share price has lost 24.8%, trading between 1.61 and 4.70.
Tweenvest scores Kintor Pharmaceutical Limited across four factors: quality 12/100, value 73/100. Its strongest factor is value.
9939 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $113.69M
- Revenue (TTM)
- $4.67M
- P/E
- —
- EPS
- -0.44
- Dividend yield
- —
- Beta (5Y)
- -0.57
- 52-week high
- HK$4.70
- 52-week low
- HK$1.61
- Avg volume (3M)
- —
- Shares outstanding
- 493.81M
- Employees
- 123
- Next earnings
- —
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
- ISIN
- KYG5273B1077
- Founded
- 2009
- Listed since
- May 22, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.72 | -0.09% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.99 | +1.06% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.30 | +0.12% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.86 | -0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.88 | -0.62% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.68 | -3.72% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.